The ADR of Investing.com – Valneva (NASDAQ :) rose more than 31% before launch on Monday as the company said the phase 3 trial of a prospective vaccine against the Covid-19 vaccine had positive results.
In this trial, Valneva candidates competed with the AstraZeneca (NASDAQ :) vaccine, one of the six most widely used vaccines against Covid in the world. Valneva argues that the results showed that the candidate had superior neutralizing antibody levels compared to vaccines from British companies.
This result may suggest that both vaccines used in the study prevented severe Covid-19 caused by circular mutations containing the predominant delta, Valneva said.
Valneva said he is preparing a trial for children aged 5 to 12 years and a booster trial to evaluate the booster immune performance of VLA2001 for people in need of the vaccine.
The company has begun filing its first approval with the UK Pharmaceutical and Medical Product Regulatory Authority and is preparing to begin its first approval with the European Medicines Agency.
The announcement will be made just weeks after the UK cancels its 100 million provisional drug orders for violating the contract. Varneva denied the allegations at the time, with external observers partially motivated by friction between the British and French governments over a bilateral agreement on the mutual implementation of Brexit agreements and the crackdown on immigrant flows across the UK channel. I saw it attached.
Stocks lost more than half of their value in response to British moves, but now have about half of those losses.
Fusion media Alternatively, anyone involved in Fusion Media will not be liable for any loss or damage resulting from relying on the data, quotes, charts, trading signals and other information contained on this website. Please be fully informed about the risks and costs associated with financial market transactions. This is one of the most risky forms of investment possible.
Valneva soars as Covid vaccine candidates promise by Investing.com
Source link Valneva soars as Covid vaccine candidates promise by Investing.com